Balaxi Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 617.24 million compared to INR 659.93 million a year ago. Revenue was INR 613.23 million compared to INR 663.04 million a year ago. Net income was INR 121.8 million compared to INR 109.52 million a year ago. Basic earnings per share from continuing operations was INR 12.18 compared to INR 10.95 a year ago. Diluted earnings per share from continuing operations was INR 12.18 compared to INR 10.95 a year ago.
For the nine months, sales was INR 1,902.89 million compared to INR 1,783.8 million a year ago. Revenue was INR 1,911.94 million compared to INR 1,808.8 million a year ago. Net income was INR 349.47 million compared to INR 297.7 million a year ago. Basic earnings per share from continuing operations was INR 34.95 compared to INR 29.77 a year ago. Diluted earnings per share from continuing operations was INR 34.95 compared to INR 29.77 a year ago.